Developing pharmacological therapies for Alzheimer disease.
Alzheimer disease (AD), while chronic and progressive with an average progression of 7 - 10 years, is both multifactorial and heterogeneous. Thus, AD offers a large window of opportunity and a large number of therapeutic targets to inhibit it. The selection of a therapeutic target, however, is one of the biggest challenges in developing a pharmacological treatment of this multifactorial disease. Inhibition of a pivotal downstream event is likely to benefit more patients than inhibition of an upstream event in AD pathogenesis. Neurofibrillary degeneration of abnormally hyperphosphorylated tau offers such a pivotal therapeutic target. Abnormal hyperphosphorylation of tau and not its aggregation into filaments appears to be the most deleterious step in neurofibrillary degeneration. Tau can be abnormally hyperphosphorylated by downregulation of protein phosphatase-2A activity or by upregulation of more than one tau kinase. Restoration of the phosphatase activity which is downregulated in AD brain or inhibition of GSK-3beta and cdk5, which are required for AD-type abnormal hyperphosphorylation of tau, are among the most promising therapeutic strategies.
Iqbal
K
K
Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, New York 10314, USA. iqbalk@worldnet.att.net
Grundke-Iqbal
I
I
D000544:Alzheimer Disease / Q000188:drug therapy*; D001921:Brain / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006801:Humans; D009410:Nerve Degeneration / Q000188:drug therapy / Q000473:pathology; D010766:Phosphorylation; D015398:Signal Transduction; D016875:tau Proteins / Q000378:metabolism*
C054369:MAPT protein, human; D016875:tau Proteins; D005947:Glucose